Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
Dave SinghJohann Christian VirchowGiorgio Walter CanonicaAndrea VeleMaxim KotsGeorge GeorgesAlberto PapiPublished in: Respiratory research (2020)
Overall, the relative efficacy of extrafine BDP/FF/G versus BDP/FF was not influenced by a range of clinical characteristics. However, some patient sub-groups gained additional benefit from BDP/FF/G for certain endpoints. In particular, for exacerbations the relative efficacy of BDP/FF/G was greater in more reversible patients. Trial registration ClinicalTrials.gov: TRIMARAN, NCT02676076 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676076?term=NCT02676076&draw=2&rank=1 ,); TRIGGER, NCT02676089 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676089?term=NCT02676089&draw=2&rank=1 ).
Keyphrases
- chronic obstructive pulmonary disease
- computed tomography
- cystic fibrosis
- preterm infants
- end stage renal disease
- ejection fraction
- dual energy
- image quality
- clinical trial
- contrast enhanced
- magnetic resonance imaging
- stem cells
- gestational age
- lung function
- prognostic factors
- positron emission tomography
- case report
- phase iii
- patient reported outcomes
- pet ct